Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2756-2764

  Parry, Christopher M ^a,b,c,n,o   Thieu, Nga Tran Vu ^a   Dolecek, Christiane ^a,b   Karkey, Abhilasha ^a   Gupta, Ruchi ^d   Turner, Paul ^b,e,f   Dance, David ^b,g   Maude, Rapeephan R ^h   Ha, Vinh ⁱ   Tran, Chinh Nguyen ⁱ   Thi, Phuong Le ^j   Van Be, Bay Pham ^j   Phi, La Tran Thi ^k   Ngoc, Rang Nguyen ^k   Ghose, Aniruddha ^l   Dongol, Sabina ^a   Campbell, James I ^a,b   Thanh, Duy Pham ^a   Thanh, Tuyen Ha ^a   Moore, Catrin E ^a,e   Sona, Soeng ^e   Gaind, Rajni ^d   Deb, Monorama ^d   Van Anh, Ho ^j   Van, Sach Nguyen ⁱ   Tinh, Hien Tran ^a,b   Day, Nicholas P J ^b,h   Dondorp, Arjen ^b,h   Thwaites, Guy ^a,b   Faiz, Mohamed Abul ^h,m   Phetsouvanh, Rattanaphone ^b,g   Newton, Paul ^b,g,n   Basnyat, Buddha ^a   Farrar, Jeremy J ^a,b   Bakera, Stephen ^a,b,n   more..

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^d SAFDARJUNG HOSPITAL   (India)

^e Angkor Hospital for Children   (Cambodia)

^f SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^g MAHOSOT HOSPITAL   (Laos)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^j Dong Thap Provincial Hospital   (Viet Nam)

^k An Giang Provincial Hospital   (Viet Nam)

^l CHITTAGONG MEDICAL COLLEGE HOSPITAL   (Bangladesh)

^m Centre for Specialized Care and Research   (Bangladesh)

ⁿ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^o NAGASAKI UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATION; CHILD; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; INHIBITION ZONE; MALE; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALMONELLA ENTERICA SEROVAR PARATYPHI A; SALMONELLA ENTERICA SEROVAR TYPHI; SINGLE DRUG DOSE; TREATMENT RESPONSE; TYPHOID FEVER; VIET NAM; ADOLESCENT; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PATHOGENICITY; SALMONELLA ENTERICA; SEROTYPE; YOUNG ADULT;

ADOLESCENT; AZITHROMYCIN; CHILD; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; SALMONELLA ENTERICA; SEROGROUP; TYPHOID FEVER; YOUNG ADULT;

EID: 84931272449     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04729-14     Document Type: Article

References (34)

1. Buckle GC, Fischer Walker CL, Black RE. 2012. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. J Glob Health 2(1):010401. http://dx.doi.org/10.7189/jogh.02.010401.
2. st century: promises and shortcomings. Clin Microbiol Infect 17:959-963. http://dx.doi.org/10.1111/j.1469-0691.2011.03552.x.
3. Chau TT, Campbell JI, Galindo CM, Hoang NVM, Diep TS, Nga TT, Chau NVV, Tuan PQ, Page AL, Ochiai RL, Schultsz C, Wain J, Bhutta ZA, Parry CM, Bhattacharya SK, Dutta S, Agtini M, Dong B, Honghui Y, Anh DD, Do GC, Naheed A, Albert MJ, Phetsouvanh R, Newton PN, Basnyat B, Arjyal A, La TT, Rang NN, Phuong LT, Bay PVB, von Seidlein L, Dougan G, Clemens JD, Vinh H, Hien TT, Chinh NT, Acosta CJ, Farrar J, Dolecek C. 2007. Antimicrobial drug resistance of Salmonella serovar Typhi in Asia and molecular mechanism of reduced susceptibility to the fluoroquinolones. Antimicrob Agents Chemother 51:4315-4323. http://dx.doi.org/10.1128/AAC.00294-07.
4. Gaind R, Paglietti B, Murgia M, Dawar R, Uzzau S, Cappuccinelli P, Deb M, Aggarwal P, Rubino S. 2006. Molecular characterization of ciprofloxacin-resistant Salmonella serovar Typhi and Paratyphi A causing enteric fever in India. J Antimicrob Chemother 58:1139-1144. http://dx.doi.org/10.1093/jac/dkl391.
5. Kariuki S, Revathi G, Kiiru J, Mengo DM, Mwituria J, Muyodi J, Munyalo A, Teo YY, Holt K, Kingsley RA, Dougan G. 2010. Typhoid in Kenya is associated with a dominant multidrug-resistant Salmonella serovar Typhi haplotype that is also widespread in Southeast Asia. J Clin Microbiol 48:2171-2176. http://dx.doi.org/10.1128/JCM.01983-09.
6. Keddy KH, Smith AM, Sooka A, Ismail H, Oliver S. 2010. Fluoroquinolone-resistant typhoid, South Africa. Emerg Infect Dis 16:879-880. http://dx.doi.org/10.3201/eid1605.091917.
7. Al Naiemi N, Zwart B, Rijnsburger MC, Roosendaal R, Debets-Ossenkopp YJ, Mulder JA, Fijen CA, Maten W, Vandenbroucke-Grauls CM, Savelkoul PH. 2008. Extended-spectrum-beta-lactamase production in a Salmonella enterica serotype Typhi strain from the Philippines. J Clin Microbiol 46:2794-2795. http://dx.doi.org/10.1128/JCM.00676-08.
8. Butler T, Sridhar CB, Daga MK, Pathak K, Pandit RB, Khakhria R, Potkar CN, Zelasky MT, Johnson RB. 1999. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother 44:243-250. http://dx.doi.org/10.1093/jac/44.2.243.
9. Girgis NI, Butler T, Frenck RW, Sultan Y, Brown FM, Tribble D, Khakhria R. 1999. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother 43: 1441-1444.
10. Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, Diep TS, Wain J, White NJ, Farrar JJ. 2000. A randomised controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid resistant enteric fever. Antimicrob Agents Chemother 44:1855-1859. http://dx.doi.org/10.1128/AAC.44.7.1855-1859.2000.
11. Frenck RW, Nakhla IA, Sultan Y, Bassily SB, Girgis FY, David J, Butler TC, Girgis NI, Morsy M. 2000. Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis 31:1134-1138. http://dx.doi.org/10.1086/317450.
12. Frenck RW, Mansour A, Nakhla I, Sultan Y, Putnam S, Wierzba T, Morsy M, Knirsch C. 2004. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis 38:951-957. http://dx.doi.org/10.1086/382359.
13. Parry CM, Ho VA, Phuong LT, Bay PVB, Lanh MN, Tung LT, Tham NTH, Wain J, Hien TT, Farrar JJ. 2007. Randomized controlled comparison of ofloxacin, azithromycin and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother 51:819-825. http://dx.doi.org/10.1128/AAC.00447-06.
14. Dolecek C, La TTP, Rang NN, Phuong LT, Vinh H, Tuan PQ, Du DC, Bay NTB, Long DT, Ha LB, Binh NT, Hong NTA, Dung PN, Lanh MN, Bay PVB, Ho VA, Hoang NVM, Nga TTT, Chau TT, Shultsz C, Dunstan SJ, Stepniewska K, Campbell JI, Diep TS, Basnyat B, Chau NVV, Sach NV, Chinh NT, Hien TT, Farrar J. 2008. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PLoS One 3:e2188. http://dx.doi.org/10.1371/journal.pone.0002188.
15. rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
16. British Society for Antimicrobial Chemotherapy. 2014. BSAC methods for antimicrobial susceptibility testing. Version 13, May 2014. http://bsac.org.uk/susceptibility/methodologylatestversion/.
17. European Committee on Antimicrobial Susceptibility Testing. 2014. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, January 2014. http://www.eucast.org/clinical-breakpoints/.
18. th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
19. Phuc Nguyen MC, Woerther PL, Bouvet M, Andremont A, Leclercq R, Canu A. 2009. Escherichia coli as reservoir for macrolide resistance genes. Emerg Infect Dis 15:1648-1650. http://dx.doi.org/10.3201/eid1510.090696.
20. Metzler DM, DeHaan RM. 1974. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis 130:588-594. http://dx.doi.org/10.1093/infdis/130.6.588.
21. rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
22. Fernando S, Molland JG, Gottlieb T. 2012. Failure of oral antibiotic therapy, including azithromycin, in the treatment of a recurrent breast abscess due to Salmonella enterica serotype Paratyphi A. Pathog Glob Health 106:366-369. http://dx.doi.org/10.1179/2047773212Y.0000000010.
23. Molloy A, Nair S, Cooke FJ, Wain J, Farrington M, Lehner PJ, Torok ME. 2010. First report of Salmonella enterica serotype Paratyphi A azithromycin resistance leading to treatment failure. J Clin Microbiol 48:4655-4657. http://dx.doi.org/10.1128/JCM.00648-10.
24. Gunell M, Kotilainen P, Jalava J, Huovinen P, Siitonen A, Hakanen AJ. 2010. In vitro activity of azithromycin against nontyphoidal Salmonella enterica. Antimicrob Agents Chemother 54:3498-3501. http://dx.doi.org/10.1128/AAC.01678-09.
25. Sjölund-Karlsson M, Joyce K, Blickenstaff K, Bell T, Haro J, Medalla FM, Fedorka-Cray P, Zhao S, Crump JA, Whichard JM. 2011. Antimicrobial susceptibility to azithromycin among Salmonella enterica isolates from the United States. Antimicrob Agents Chemother 55:3985-3989. http://dx.doi.org/10.1128/AAC.00590-11.
26. Dutta S, Das S, Mitra U, Jain P, Roy I, Ganguly SS, Ray U, Dutta P, Paul DK. 2014. Antimicrobial resistance, virulence profiles and molecular subtypes of Salmonella enterica serovars Typhi and Paratyphi A blood isolates from Kolkata, India during 2009-2013. PLoS One 9:e101347. http://dx.doi.org/10.1371/journal.pone.0101347.
27. Butler TC, Frenck RW, Johnson RB, Khakhria R. 2001. In vitro effects of azithromycin on Salmonella typhi: early inhibition by concentrations less than the MIC and reduction of MIC by alkaline pH and small inocula. J Antimicrob Chemother 47:455-458. http://dx.doi.org/10.1093/jac/47.4.455.
28. Foulds G, Shepard RM, Johnson RB. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25(Suppl A):73-82. http://dx.doi.org/10.1093/jac/25.suppl-A.73.
29. Panteix G, Guillaumond B, Harf R, Desbos A, Sapin V, Leclercq M, Perrin-Fayolle M. 1993. In-vitro concentration of azithromycin in human phagocytic cells. J Antimicrob Chemother 31(Suppl E):1-4. http://dx.doi.org/10.1093/jac/31.suppl-E.1.
30. Rakita RM, Jaques-Palaz K, Murray BE. 1994. Intracellular activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother 38:1915-1921. http://dx.doi.org/10.1128/AAC.38.9.1915.
31. Van Bambeke F, Tulkens PM. 2001. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 18:S17-S23. http://dx.doi.org/10.1016/S0924-8579(01)00406-X.
32. Kobayashi T, Hayakawa K, Mawatari M, Mezaki K, Takeshita N, Kutsuna S, Fujiya Y, Kanagawa S, Ohmagari N, Kato Y, Morita M. 2014. Case report: failure under azithromycin treatment in a case of bacteremia due to Salmonella enterica Paratyphi A. BMC Infect Dis 14:404. http://dx.doi.org/10.1186/1471-2334-14-404.
33. Hassing RJ, Goessens WHF, van Pelt W, Mevius DJ, Stricker BH, Molhoek N, Verbon A, van Genderen PJJ. 2014. Salmonella subtypes with increased MICs for azithromycin in travellers returned to the Netherlands. Emerg Infect Dis 20:705-708. http://dx.doi.org/10.3201/eid2004.131536.
34. Rai S, Jain S, Prasad KN, Ghoshal U, Dhole TN. 2012. Rationale of azithromycin prescribing practices for enteric fever in India. Indian J Med Microbiol 30:30-33. http://dx.doi.org/10.4103/0255-0857.93017.